Onchocerciasis: Developments in diagnosis, treatment and control

International Journal of Dermatology

Volumn 48, Issue 4, 2009, Pages 393-396

  Stingl, Peter ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CHLORAMPHENICOL; CIPROFLOXACIN; DIETHYLCARBAMAZINE; DOXYCYCLINE; ERYTHROMYCIN; IVERMECTIN; MINOCYCLINE; RIFAMPICIN; SURAMIN;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; NEUROLOGIC DISEASE; NONHUMAN; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; PARASITE TRANSMISSION; PATCH TEST; PUBLIC HEALTH; SENSITIVITY AND SPECIFICITY; SKIN TOXICITY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VECTOR CONTROL; WOLBACHIA;

ANTIPARASITIC AGENTS; COMMUNICABLE DISEASE CONTROL; HUMANS; IVERMECTIN; ONCHOCERCIASIS; WORLD HEALTH;

EID: 63249091907     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.03843.x     Document Type: Article

References (31)

1. Burnham G. Onchocerciasis. Lancet 1998; 351: 1341-1346.
2. Remme JHF. Research for control: The onchocerciasis experience. Trop Med Int Health 2004; 9: 243-254.
3. Nguyen JC, Murphy ME, Nutman TB, et al. Cutaneous onchocerciasis in an American traveler. Int J Derm 2005; 44: 125-128.
4. Udall D. Recent updates on onchocerciasis: Diagnosis and treatment. CID 2007; 44: 53-60.
5. Ackermann SJ, Kephart GM, Francis H, et al. Eosinophil degranulation. An immunologic determinant in the pathogenesis of the Mazotti reaction in human onchocerciasis. J Immunol 1990; 144: 3961-3969.
6. King CL, Nutman TB. Regulation of the immune response in lymphatic filariasis and onchocerciasis. Immunol Today 1992; 12: A54-A58.
7. Stingl P. Onchocerciasis: Clinical presentation and host parasitic interactions in patients of Southern Sudan. Int J Dermatol 1997; 36: 23-28.
8. Carlier Y, Truyens C. Influence of maternal infection on offspring resistance towards parasites. Parasitol Today 1995; 11: 94-99.
9. Osei-Atweneboana MY, Eng JK, Boakye DA, et al. Prevalence and intensity of Ov infection and efficacy of ivermectin in endemic communities in Ghana: A two-phase epidemilogical study. Lancet 2007; 369: 2021-2029.
10. Ayong LS, Tume CB, Wembe FE, et al. Development and evaluation of an antigen detection dipstick assay for the diagnosis of human onchocercisis. Trop Med Int Health 2005; 10: 228-223.
11. Boatin BA, Toe L, Alley ES, et al. Diagnostics on onchocerciasis: Future challenges. Ann Trop Med Parasitol 1998; 92: 41-45.
12. Langham ME, Traub ZD, Richardson R. A transepidermal chemotherapy of onchocerciasis. Tropenmed Parasitol 1978; 29: 156-162.
13. Taylor HR, Greene BM, Langham ME. Controlled clinical trial of oral and topical diethylcarbamazine in treatment of onchocerciasis. Lancet 1980; 1: 943-946.
14. Stingl P, Ross M, Gibson DW, et al. A diagnostic "patch test" for onchocerciasis using topical diethylcarbamazine. Trans R Soc Trop Med Hyg 1984; 78: 254-258.
15. Ozoh G, Boussinesq M, Zoung-Kanyi Bissek AC, et al. Evaluation of the diethylcarbamazine patch to evaluate onchocerciasis endemicity in Central Africa. Trop Med Int Health 2007; 12: 123-129.
16. Boussinesq M, Kamgno J, Eloundou Onomo P, et al. Evaluation du patch a la DEC chez les sujets infectes par Loa loa. Document du Laboratoire mixte CPC/ORSTOM d'Epidemiologie et de Sante publique 1998; 98-16. Centre Pasteur, Yaunde, Cameroon.
17. Roberts JMD, Neumann E, Gockel CW, et al. Onchocerciasis in Kenya 9, 11, and 18 years after elimination of the vector. Bull of the World Health Organ 1967; 37: 195-212.
18. Aziz MA, Diallo S, Kiop IM et al. Efficacy and tolerance of ivermectin in onchocerciasis. Lancet 1982; 2: 171-173.
19. Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: Pharmacology and application in dermatology. Int J Derm 2005; 44: 981-988.
20. Bourguinat C, Pion SDS, Kamgno J, et al. Genetic selection of low fertile Ov by ivermectin treatment. Plos Negl Trop Dis 2007; 1: E72.
21. Hoerauf A, Volkmann L, Hamelmann C, et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet 2000; 355: 1242-1243.
22. Hoerauf A, Mand S, Adjei O, et al. Depletion of Wolbachia endobacteria in Ov by doxycycline and microfilaridermia after ivermectin treatment. Lancet 2001; 357: 1415-1416.
23. Hoerauf A, Mand S, Volkmann L, et al. Doxycycline in the treatment of human onchocerciasis: Kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms. Microbes Infect 2003; 5: 261-273.
24. Debrah AY, Mand S, Marfo-Debrekyli Y, et al. Assessment of microfilarial loads in the skin of onchocerciasis patients after treatment with different regimens of doxycycline plus ivermectin. Filaria J 2006; 5: 1.
25. Volkmann L, Fischer K, Taylor M, et al. Antibiotic therapy in murine filariasis (Litomosoides sigmodontis): Comparative effects of doxycycline and rifampicin on Wolbachia and filarial viability. Trop Med Int Health 2003; 8: 392-401.
26. Hoerauf A, Volkmann L, Nissen-Pehle K, et al. Targeting of Wolbachia endobacteria in Litomosoides sigmodontis: Comparison of tetracyclines with chloramphenicol, macrolides and ciprofloxacin. Trop Med Int Health 2000; 5/4: 275-279.
27. Debrah AY, Mand S, Marfo-Debrekyli Y, et al. Macrofilaricidal effect of 4 weeks of treatment with doxycycline on Wuchereria bancrofti. Trop Med Int Health 2007; 12: 1433-1441.
28. Tielsch MJ, Beeche A. Impact of ivermectin on illness and disability associated with onchocerciasis. Trop Med Int Health 2004; 9: A45-A56.
29. Waters HR, Rehwinkel JA, Burnham G. Economic evaluation of Mectizan distribution. Trop Med Int Health 2004; 9: A16-A25.
30. Burnham G, Mebrahtu T. The delivery of ivermectin. Trop Med Int Health 2004; 9: A26-A44.
31. Dadzie Y, Neira M, Hopkins D. Final report of the Conference on the eradicability of onchocerciasis. Filaria J 2003; 2: 2.